



LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES
Pharmacy Affairs

September 13th, 2022

TO: MHLA Clinics
FROM: DHS Pharmacy Affairs
RE: DHS MHLA Formulary Update

MY HEALTH LA FORMULARY

Due to recent 340B distribution restrictions placed by Boehringer Ingelheim, multiple MHLA formulary changes will be made. **The formulary amendments outlined below will go into effect on 09/14/2022.** We appreciate your efforts to ensure MHLA participants' continuity of care and strongly encourage MHLA Clinics to proactively work with your 340B contract pharmacies as we navigate through these manufacturer-mandated 340B distribution restrictions.

UPDATE – Formulary Amendment (effective date 09/14/2022)

Drug Product	Comments
Atrovent® HFA	<p>Atrovent® claims will reject at <u>contract 340B pharmacies</u> with the message: “Not cvd. Use Ipratropium Neb or call CCT”</p> <p>If you are calling from a contract pharmacy servicing a MHLA participant from a MHLA clinic that:</p> <ul style="list-style-type: none"> • <u>Has an On-Site Pharmacy or Dispensary:</u> CCT will advise you to direct the MHLA participant to their MHLA Clinic on-site pharmacy and transfer prescription as appropriate. If the participant is unable to travel to their on-site clinic pharmacy or dispensary, please contact the prescriber for alternative formulary options, including <u>temporary formulary allowance Ipratropium Bromide inhalation solution for nebulizer.</u> • <u>Does NOT have an On-site Pharmacy or Dispensary:</u> CCT will advise you to contact the prescriber for alternative formulary options, including <u>temporary formulary allowance of Ipratropium Bromide inhalation solution for nebulizer.</u> <p><u>NOTE:</u> BI distribution restrictions do NOT apply to On-Site Pharmacies and Dispensaries. Atrovent® will continue to process according to prior formulary restrictions at these locations.</p>

This document contains confidential information intended for MHLA Program Healthcare Providers and Professionals. Unintended recipients may not disclose, copy, distribute, or take any action based on this document. This information is not to be disclosed to pharmaceutical representatives, press, or other outside agents.

<p>Januvia® 25mg, 50mg and 100mg oral tablets & Tradjenta® 5mg oral tablets</p>	<p>Januvia® and Tradjenta® claims will reject at <u>contract 340B pharmacies</u> with the message: “Not cvd. Consider Nesina or call CCT”</p> <p>If you are calling from a contract pharmacy servicing a MHLA participant from a MHLA clinic that:</p> <ul style="list-style-type: none"> • <u>Has an On-Site Pharmacy or Dispensary:</u> CCT will advise you to direct the MHLA participant to their MHLA Clinic on-site pharmacy and transfer prescription as appropriate. If the participant is unable to travel to their on-site clinic pharmacy or dispensary, please contact the prescriber for alternative formulary options, including <u>temporary formulary allowance of Nesina®</u>. • <u>Does NOT have an On-site Pharmacy or Dispensary:</u> CCT will advise you to contact the prescriber for alternative formulary options, including <u>temporary formulary allowance of Nesina®</u>. <p>NOTE: Merck and BI distribution restrictions do NOT apply to On-Site Pharmacies and Dispensaries. Januvia® and Tradjenta® will continue to process MHLA according to prior formulary restrictions at these locations.</p>
<p>Clonidine 0.1mg/24hr, 0.2mg/24hr and 0.3mg/24hr transdermal patch</p>	<p>Restricted to generic only; Catapres-TTS® no longer covered</p>
<p>Jardiance® 25mg oral tablets</p>	<p>Jardiance® claims will reject at <u>contract 340B pharmacies</u> with the message: “Not cvd. Consider Invokana or call CCT”</p> <p>If you are calling from a contract pharmacy servicing a MHLA participant from a MHLA clinic that:</p> <ul style="list-style-type: none"> • <u>Has an On-Site Pharmacy or Dispensary:</u> CCT will advise you to direct the MHLA participant to their MHLA Clinic on-site pharmacy and transfer prescription as appropriate. If the participant is unable to travel to their on-site clinic pharmacy or dispensary, please contact the prescriber for alternative formulary options, including <u>temporary formulary allowance of Invokana®</u>. • <u>Does NOT have an On-site Pharmacy or Dispensary:</u> CCT will advise you to contact the prescriber for alternative formulary options, including <u>temporary formulary allowance of Invokana®</u>. <p>NOTE: BI distribution restrictions do NOT apply to On-Site Pharmacies and Dispensaries. Jardiance® will continue to process at according to prior formulary restrictions at these locations. Jardiance®/Invokana® PA form required for treatment initiation of either product. No additional PA needed for patients transitioning from Jardiance® to Invokana® due to above manufacturer restriction.</p>

<p>Spiriva® Handihaler 18mcg inhalation capsules</p>	<p>Spiriva® claims will reject at <u>contract 340B pharmacies</u> with the message: “Not cvd. Consider Incruse or call CCT”</p> <p>If you are calling from a contract pharmacy servicing a MHLA participant from a MHLA clinic that:</p> <ul style="list-style-type: none">• <u>Has an On-Site Pharmacy or Dispensary:</u> CCT will advise you to direct the MHLA participant to their MHLA Clinic on-site pharmacy and transfer prescription as appropriate. If the participant is unable to travel to their on-site clinic pharmacy or dispensary, please contact the prescriber for alternative formulary options, including <u>temporary formulary allowance of Incruse®</u>.• <u>Does NOT have an On-site Pharmacy or Dispensary:</u> CCT will advise you to contact the prescriber for alternative formulary options, including <u>temporary formulary allowance of Incruse®</u>. <p><u>NOTE:</u> BI distribution restrictions do NOT apply to On-Site Pharmacies and Dispensaries. Spiriva® will continue to process according to prior formulary restrictions at these locations.</p>
--	---